Drug Profile
Research programme: cancer therapeutics - Siamab Therapeutics
Alternative Names: Anti-glycan antibodies; Anti-Neu5Gc antibodies - Sialix; Anti-Sialyl-Tn antibodies; Anti-Sialyl-Tn monoclonal antibodies; Anti-STn antibodies; Humanised anti-Sialyl-Tn anti-CD3 bispecific antibodies; SIA01-ADC; SIA02-ADC; ST1; ST1 antibody drug conjugate programmeLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Sialix
- Developer Massachusetts General Hospital; Siamab Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Polysaccharide inhibitors; Sialosyl Tn antigen inhibitors; Tumour-associated carbohydrate antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (SC)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)